Short answer
Yes—and also: it depends. Plain cough drops and lozenges commonly sold as candy (menthol, honey or pectin-based) typically provide short-lived symptomatic relief by coating the throat and changing how sensory nerves perceive irritation. Some lozenges that contain active drugs (local anaesthetics like benzocaine or lidocaine, anti-inflammatories like low‑dose flurbiprofen, or antitussive molecules such as dextromethorphan in lozenge form) have trial evidence of extra benefit for sore throat or cough. But high-quality systematic reviews find surprisingly little consistent evidence that generic over‑the‑counter cough medicines produce reliable, clinically important reductions in cough; results vary by ingredient, formulation, dose and study quality.
How cough drops work — the biology in plain English
Most cough drops rely on one or more of these mechanisms:
1) Demulcent/coating effect: pectin, glycerin, honey and other syrupy bases coat the irritated mucous membranes. That physical film soothes raw tissues, reduces friction from swallowing, and can reduce the urge to clear the throat. Several lozenge trials demonstrate a rapid soothing effect the moment a lozenge starts to dissolve—this is the demulcent at work.
2) Sensory modulation (menthol/cooling): menthol activates cold-sensitive TRPM8 receptors on sensory nerves, producing a cooling sensation in the throat and nasal cavity that can suppress cough reflex sensitivity in animal and human models. Menthol can also alter the perception of airway irritation without changing the underlying inflammation.
3) Local anaesthesia/analgesia: benzocaine, lidocaine and ambroxol in lozenges numb the mucosa locally, reducing pain and the reflexive cough that comes from throat pain or irritation. Clinical trials show these agents can reduce sore-throat pain beyond the soothing base.
4) Pharmacologic antitussives or anti‑inflammatories: some lozenges contain small doses of true drugs (e.g., dextromethorphan in lozenge form or low‑dose NSAIDs such as flurbiprofen) that may suppress cough or inflammation through central or local mechanisms.
5) Antimicrobial or mineral effects (zinc): zinc lozenges have been tested for treatment of the common cold; proposed actions include direct antiviral effects in vitro and local effects in the oropharynx. Evidence for benefit is mixed and depends strongly on formulation and dosing.
6) Placebo and behavioral effects: sucking a lozenge is an attention‑focusing action; placebo effects are strong for subjective symptoms (throat pain, cough frequency reported by the patient).
What the best reviews and trials find
Systematic reviews examining OTC cough medicines overall conclude there is no consistent, high‑quality evidence that generic OTC cough-and-cold products reliably reduce cough for adults or children beyond placebo. (Major Cochrane reviews summarize the uncertainty.)
For children, honey shows some benefit for acute cough symptoms versus placebo or no treatment in small trials (but honey must not be given to infants under 12 months).
Zinc lozenges: older and recent randomized trials and meta-analyses give mixed results. Some studies (particularly with higher elemental zinc doses and certain zinc-acetate formulations given frequently while symptomatic) show shorter cold duration and reduced symptom severity; other trials show little or no benefit. Recent evidence reviews call for better‑standardized, well‑conducted trials before recommending zinc lozenges universally.
Medicated lozenges: well‑designed RCTs show that lozenges containing local anaesthetics (benzocaine/lidocaine), ambroxol, or low‑dose NSAIDs (e.g., flurbiprofen 8.75 mg) provide faster and greater sore‑throat relief than an inert demulcent lozenge. That demonstrates a pharmacologic effect beyond mere 'candy'.
Overall: if you want temporary symptom relief while a viral infection runs its course, many people will feel helped by lozenges. However, for meaningful, objectively measured reductions in cough frequency or cold duration the data are inconsistent and ingredient‑dependent.
Safety and special cautions
Children: the FDA and pediatric authorities advise against giving most OTC cough-and-cold medications to very young children because of safety concerns and lack of proven benefit. Sucking lozenges is a choking hazard under about age 4; many pediatric guidelines recommend lozenges only for older children and with parental supervision.
Benzocaine and methemoglobinemia: some lozenges/sprays contain benzocaine or related topical anaesthetics. Benzocaine has been linked to methemoglobinemia (a rare but potentially serious reduction in the blood’s oxygen‑carrying capacity); product labels and FDA communications carry warnings. Use benzocaine products only as directed and seek care for symptoms such as rapid heart rate, cyanosis, shortness of breath, or unusual tiredness.
Intranasal zinc products (not lozenges): the FDA warned consumers in 2009 after reports that certain intranasal zinc products (Zicam nasal gels/swabs) were associated with loss of smell (anosmia). That risk applied to intranasal zinc formulations, not to oral lozenges, but it underscores that formulation and route matter.
Dextromethorphan and interactions/abuse: dextromethorphan appears in some cough products (including lozenges). At recommended doses it is generally safe for adults but it has abuse potential at high doses and interacts with monoamine oxidase inhibitors (MAOIs) and some antidepressants—read labels and consult a clinician if you take other medications.
Allergies and product content: read labels (sugars for diabetics, salicylates/NSAIDs if you have bleeding risk or ulcer history, menthol/eucalyptus if you have airway hyperreactivity).
Practical guidance — what to expect and when to see a doctor
Expect short, symptom‑focused relief: a lozenge commonly reduces throat scratchiness and may reduce the urge to cough for a short time. Menthol lozenges feel cooling and distracting; pectin/honey lozenges coat and soothe.
If you want a measurable drug effect for sore throat, choose products with trial‑backed actives (e.g., flurbiprofen lozenges or local anaesthetic lozenges) and follow the label. Real benefit requires appropriate dosing and formulation.
Don’t give lozenges to young children who may choke (typically under 4). For infants under 12 months, do not give honey. For persistent, severe, worsening, or blood‑streaked cough, or symptoms >2–3 weeks, see a clinician because some causes need specific treatment.
If you have heart disease, are pregnant, take MAOIs, or have other chronic illnesses, check with a pharmacist or doctor before using medicated lozenges with active drugs.
Bottom line
Cough drops often 'work' for subjective, short‑term relief because they coat the throat and change sensory signals (menthol and demulcents). A subset of medicated lozenges provides additional, trial‑proven benefit for sore throat or cough. But broad claims that all OTC cough drops or cold medicines shorten colds or reliably stop coughs are not supported by consistent high‑quality evidence. Use them as symptomatic relief, follow age and safety warnings, and seek medical attention for prolonged or severe symptoms.
Sources reviewed
- Cochrane: Over-the-counter (OTC) medications for acute cough in children and adults in community settings — Authoritative systematic review summarising clinical trial evidence about OTC cough medicines.
- Cochrane: Honey for acute cough in children — Best-available evidence for honey as a symptomatic treatment in children.
- Cochrane: Zinc for the prevention and treatment of the common cold — Recent systematic review capturing modern zinc lozenge trials and heterogeneity of evidence.
- Mayo Clinic: Cough and cold remedies: What works, what doesn't — Clinically oriented summary and practical advice from a major US medical centre.
- PubMed / Clinical Trial: Efficacy of a benzocaine lozenge in the treatment of uncomplicated sore throat — Randomized trial showing analgesic effect of benzocaine lozenge vs placebo.
- PMC / Journal article: Ambroxol hard‑boiled lozenges randomized double-blind placebo-controlled trial — High-quality RCT for an active lozenge ingredient with demonstrated efficacy beyond demulcent effect.
- PubMed / International Journal of Clinical Practice: Relief of sore throat with the anti‑inflammatory throat lozenge flurbiprofen 8.75 mg: randomized placebo‑controlled study — Example of an NSAID lozenge showing benefit over demulcent placebo.
- PMC / Journal article: Menthol and cough: TRPM8 and antitussive mechanisms — Mechanistic evidence that menthol can reduce cough reflex sensitivity via TRPM8 activation.
- U.S. Food & Drug Administration (FDA): FDA consumer update: Should you give kids medicine for coughs and colds? — Authoritative safety guidance for use of cough medicines in children.
- U.S. Food & Drug Administration (FDA): FDA: Risk of serious and potentially fatal blood disorder prompts action (benzocaine warnings) — Primary safety communications and label changes about benzocaine and methemoglobinemia risk.
- FDA / PLOS / CDC reporting: Zicam intranasal zinc products and anosmia — FDA advisory and research — Documented safety issue for intranasal zinc products and mechanistic evidence of olfactory damage.